

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) March 31, 2021

EYENOVIA, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation)

001-38365

(Commission File Number)

47-1178401

(IRS Employer Identification No.)

295 Madison Avenue, Suite 2400, New York, New York 10017

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code (917) 289-1117

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.0001 Par Value	EYEN	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this Chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this Chapter).

Emerging growth company ☒ x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(d) On March 31, 2021, the Board of Directors (the “Board”) of Eyenovia, Inc. (the “Company”) appointed Julia A. Haller, M.D. as a member of the Board, effective immediately, to serve until the Company’s 2021 annual meeting of stockholders or until her successor is duly elected and qualified.

Dr. Haller, age 66, has served since 2007 as Ophthalmologist-in-Chief at Wills Eye Hospital in Philadelphia, PA, where she holds the William Tasman, M.D. Endowed Chair. She also is Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University and Thomas Jefferson University Hospitals. Prior to her current positions, Dr. Haller trained at the Wilmer Eye Institute at Johns Hopkins where she served as the first female Chief Resident. She then joined the Johns Hopkins faculty, where she directed the retina fellowship program and held the Katharine Graham Chair in Ophthalmology. One of the world's most renowned retinal surgeons, Dr. Haller has published over 400 scientific articles and book chapters and innovated translational advances against blindness in many areas. Elected to the National Academy of Medicine, Dr. Haller is recognized globally for her multiple accomplishments in ophthalmology. Dr. Haller currently serves on the board of directors of Bristol-Myers Squibb Company (NYSE: BMY) and served on the board of directors of Celgene Corporation, prior to its acquisition by Bristol-Myers Squibb in 2019. She also is president and serves on the board of directors of the Women in Medicine Legacy Foundation, chairs the Heed Foundation and Society of Heed Fellows, is a member of the board of directors of the College of Physicians of Philadelphia, Johns Hopkins Medical and Surgical Association, and the Philadelphia Orchestra Association, and is a member of the American Ophthalmological Society Council, and the American Academy of Ophthalmology Foundation board of advisors. Dr. Haller’s editorial board service includes RETINA, Retinal Physician, Retina Times, Ocular Surgery News, Retina Today, and Ophthalmology Times. Dr. Haller holds an A.B. in philosophy from Princeton University, where she graduated magna cum laude, and an M.D. from Harvard University Medical School.

The Board has determined that Dr. Haller is an independent director under relevant SEC and Nasdaq rules. There are no arrangements or understandings between Dr. Haller and any other person pursuant to which she was appointed as a director of the Board. There have been no transactions in which the Company has participated and in which Dr. Haller has had a direct or indirect material interest that would be required to be disclosed under Item 404(a) of Regulation S-K. Dr. Haller has not been appointed to any Board committee at this time.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release dated April 1, 2021.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

EYENOVIA, INC.

Date: April 1, 2021

By: /s/ John Gandolfo
Name: John Gandolfo
Title: Chief Financial Officer



Eyenovia Announces Appointment of Renowned Ophthalmologist and Scientific Leader Dr. Julia Haller to its Board of Directors

NEW YORK – April 1, 2021—Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology, today announced the appointment of renowned ophthalmologist and scientific leader, Julia Haller, M.D., to its Board of Directors.

“We are delighted to welcome Dr. Haller to our Board of Directors at such an exciting time for Eyenovia,” commented Dr. Sean Ianchulev, Chief Executive Officer and Chief Medical Officer of Eyenovia. “We believe that Dr. Haller’s decades of experience as an esteemed ophthalmic surgeon, scientist, professor, and business leader will be invaluable to the Eyenovia team as we strive to advance our late-stage ophthalmic pipeline and work towards our near-term clinical and regulatory milestones.”

“I have been familiar with Eyenovia and its MAP technology for some time now and believe the Company’s proprietary programs have the potential to become new standards of care in ophthalmic indications with significant unmet needs,” stated Dr. Haller. “I look forward to working with my fellow Eyenovia Board members and the leadership team to help create advances in the field.”

Since 2007, Dr. Haller has served as Ophthalmologist-in-Chief at Wills Eye Hospital in Philadelphia, where she holds the William Tasman, M.D. Endowed Chair. She also is Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University and Thomas Jefferson University Hospitals.

One of the world’s most renowned retinal surgeons, Dr. Haller has published over 400 scientific articles and book chapters and innovated translational advances against blindness in many areas. Elected to the National Academy of Medicine, Dr. Haller, has been awarded the Rolex Achievement Award, the American Academy of Ophthalmology (AAO) Honor Award, the AAO Senior Achievement Award, the Vitreous Society Senior Honor Award, the Crystal Apple Award (for mentorship) of the American Society of Retina Specialists (ASRS), the Kreissig Award from EURETINA, the President’s Award from Women in Ophthalmology (WIO), a Secretariat Award from the AAO, the Gertrude Pyron Award from the Retina Research Foundation/ASRS, a Lifetime Achievement Award from the AAO, the Louis Braille Award from Associated Services for the Blind, the Heed Award from the Society of Heed Fellows, the Gass Medal from the Macula Society, the Strittmatter Award from the Philadelphia Medical Society (their highest honor), the AAO EnerGEYES Award, the WIO Suzanne Véronneau-Troutman Award, the Charles L. Schepens, MD, Award from the Retina Research Foundation/AAO and election to the Johns Hopkins Society of Scholars. She holds Chair XVI of the Academia Ophthalmologica Internationalis.

Dr. Haller serves on the board of directors of Bristol-Myers Squibb Company. She also serves as president and board member for the Women in Medicine Legacy Foundation. Dr. Haller chairs the Heed Foundation and Society of Heed Fellows, is a member of the board of directors of the College of Physicians of Philadelphia, Johns Hopkins Medical and Surgical Association, and the Philadelphia Orchestra Association, and is a member of the American Ophthalmological Society Council and the American Academy of Ophthalmology Foundation board of advisors. She is past president of the Retina Society and the American Society of Retina Specialists and was previously a member of the Board of Trustees of the Association of University Professors of Ophthalmology, as well as a founding member of Women in Retina. Her editorial board service includes RETINA, Retinal Physician, Retina Times, Ocular Surgery News, Retina Today, and Ophthalmology Times.



Dr. Haller was educated at Princeton University, where she graduated magna cum laude, and at Harvard Medical School, where she earned her M.D. She trained at the Wilmer Eye Institute at Johns Hopkins, where she served as the first female Chief Resident. She then joined the Johns Hopkins faculty, where she directed the retina fellowship program and held the Katharine Graham Chair in Ophthalmology before her current position leading Wills Eye Hospital.

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic company developing a pipeline of advanced therapeutics based on its proprietary microdose array print (MAP™) platform technology. Eyenovia is currently focused on the late-stage development of medications for presbyopia, myopia progression and mydriasis. For more information, visit www.eyenovia.com.

Forward-Looking Statements

Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: our ability to attract and retain key personnel; risks of our and our licensees' clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; the timing and our and our licensees' ability to submit applications for, obtain and maintain regulatory approvals for our product candidates; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.

Eyenovia Contact:

Eyenovia, Inc.
John Gandolfo
Chief Financial Officer
jgandolfo@eyenovia.com

Eyenovia Investor Contact:

Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363

Eyenovia Media Contact:

Sam Choinski
Pazanga Health Communications
schoinski@pazangahealth.com
(603) 489-5964
